Antisense downregulation of mutant huntingtin in a cell model

Lis Hasholt1, Kathrine Abell, Anne Nørremølle

  • 1Section of Neurogenetics, Institute of Medical Biochemistry and Genetics, University of Copenhagen, Denmark. hasholt@imbg.ku.dk

Insights

Antisense oligonucleotides effectively reduce mutant huntingtin expression and aggregate formation in cellular models of Huntington's disease (HD). This suggests a potential therapeutic strategy for HD by downregulating the disease-causing protein.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Huntington's disease (HD) is an inherited neurodegenerative disorder.
  • Caused by CAG repeat expansion in the huntingtin (HD) gene, leading to mutant huntingtin protein.
  • Pathological mechanisms involve mutant huntingtin expression and neuronal death.

Purpose of the Study:

  • Investigate the potential of antisense technique to downregulate mutant huntingtin expression.
  • Assess the effect of antisense oligonucleotides on huntingtin aggregation.

Main Methods:

  • Transfection of NT2 cells and neurons with HD gene constructs.
  • Treatment with phosphorothioated antisense oligonucleotides (PS-ASHD/20+) or control oligonucleotides.
  • Monitoring of fusion protein expression and aggregate formation.

Main Results:

  • Antisense oligonucleotides specifically inhibited fusion protein expression and aggregate formation.
  • Effectiveness observed in both NT2 precursor cells and differentiated neurons.
  • Antisense effect in NT2 cells was administration-dependent.

Conclusions:

  • Phosphorothioated antisense oligonucleotides are effective in downregulating mutant huntingtin.
  • Reduced aggregate formation serves as a sensitive biological marker for HD.
  • Antisense huntingtin knockdown is a promising therapeutic strategy for HD and useful for cellular model studies.
Abstract